Research Reports

Key takeaways

Daniel Burton retired as CEO effective February 12, 2026, and from the Board effective February 17, 2026.

Burton to serve as Strategic Advisor from March 1, 2026, through December 31, 2026, with $10,000 monthly salary.

All unvested equity awards forfeited as of March 3, 2026.

Transition supports orderly handover of CEO responsibilities.

Agreement includes general release of claims and non-disparagement.

Burton subject to ongoing confidentiality and non-compete during transition.

Full analysis

Daniel Burton's accelerated retirement from the CEO role on February 12, 2026, prompted a structured transition via the March 31, 2026, agreement, retaining him as Strategic Advisor through year-end at reduced pay of $10,000 monthly. This ensures continuity in leadership handover, with Burton performing transitional duties while forfeiting all unvested equity post-March 3, 2026. The arrangement includes compliance with confidentiality, non-compete, and SEC reporting obligations, alongside mutual non-disparagement, signaling an amicable separation without admission of fault.

HCAT · Health Catalyst, Inc.

Summary

Key takeaways

Full analysis